Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00971191 · ClinicalTrials.gov registry record · Phase 1
A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00971191 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 22 participants.
The verdict
NCT00971191, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will enroll patients who are planned to undergo surgical removal of their tumor. The goal of the study is to evaluate the changes that occur in the tumor after brief (about 8 days) exposure to the study drug.
Interventions
- DRUG PF-00299804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00971191
The ClinicalTrials.gov registry entry for NCT00971191 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-00299804 is the first listed.
NCT00971191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00971191 about?
NCT00971191 is a clinical study titled "A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804". This study will enroll patients who are planned to undergo surgical removal of their tumor. The goal of the study is to evaluate the changes that occur in the tumor after brief (about 8 days) exposure to the study drug.
What is the current status of trial NCT00971191?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2010-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00971191?
The interventions under investigation include: PF-00299804 (DRUG).
Who is sponsoring clinical trial NCT00971191?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.